FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm – ILCN.org (ILCN/WCLC)
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC.